Grifols: all 108 studies

Page 1 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaRecruitingNCT07582432Phase 3
• A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)RecruitingNCT07555483Phase 3
• A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT07540221Phase 3
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus InfectionRecruitingNCT07024641Phase 1
• A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT06258304Phase 1
• Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)RecruitingNCT05722938Phase 3
• A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 3
• Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyEnrolling by invitationNCT02796937Phase 3
• A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)TerminatedNCT05038020Phase 2Results posted
• Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on HemodialysisCompletedNCT04985383Not applicableResults posted
• A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory OutpatientsTerminatedNCT04847141Phase 3Results posted
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT04722887Phase 1/2Results posted
• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyCompletedNCT04566692Phase 4Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyCompletedNCT04561115Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)TerminatedNCT04547140Phase 2Results posted
• A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive ImpairmentCompletedNCT04527328Not applicableResults posted
• A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous PemphigoidTerminatedNCT04499235Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)CompletedNCT04480424Phase 2Results posted
• Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentCompletedNCT04369430Phase 2Results posted
• A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMDCompletedNCT04331730Phase 2Results posted
• A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee ArthroplastyCompletedNCT03981419Phase 2Results posted
• A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's DiseaseCompletedNCT03765762Phase 2Results posted
• A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentCompletedNCT03713957Phase 2Results posted
• Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%TerminatedNCT03702920Phase 3Results posted
• Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular DegenerationCompletedNCT03558074Phase 2Results posted
• Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular DegenerationCompletedNCT03558061Phase 2Results posted
• A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT03520998Phase 2Results posted
• A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric ParticipantsCompletedNCT03461406Phase 3Results posted
• Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-ADCompletedNCT03461276Phase 2Results posted
• Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesCompletedNCT03451292Phase 3Results posted
• Adjusted Fibrinogen Replacement StrategyCompletedNCT03444324Phase 3Results posted
• Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)CompletedNCT03351933Phase 4Results posted
• Alphanate in Immune Tolerance Induction TherapyTerminatedNCT03095287Phase 2Results posted
• Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia BCompletedNCT03091751Phase 2Results posted
• Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral SclerosisCompletedNCT02872142Phase 2Results posted
• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)CompletedNCT02870348Phase 1/2Results posted
• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT02870309Phase 1/2Results posted
• Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PIDCompletedNCT02810444Phase 3Results posted
• Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02806986Phase 3Results posted
• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02604810Phase 3Results posted
• Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus ErythematosusCompletedNCT02554019Phase 2Results posted
• Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral SclerosisCompletedNCT02479802Phase 2Results posted
• Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisCompletedNCT02473965Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisCompletedNCT02473952Phase 2Results posted
• A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsCompletedNCT02413580Phase 3Results posted
• A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin DeficiencyCompletedNCT02282527Phase 2/3Results posted
• Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaCompletedNCT02281500Phase 1/2Results posted
• Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio SyndromeTerminatedNCT02176863Phase 2/3Results posted
• Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes MellitusTerminatedNCT02093221Phase 2Results posted
• Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyCompletedNCT02065882Phase 3Results posted
• Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary BypassCompletedNCT02037555Phase 2Results posted
• Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During SurgeryCompletedNCT02014402Phase 2Results posted
• Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid ArthritisTerminatedNCT01999192Phase 2Results posted
• Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open SurgeriesCompletedNCT01754480Phase 3Results posted
• Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open SurgeriesCompletedNCT01731938Phase 3Results posted
• Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic FibrosisCompletedNCT01684410Phase 2Results posted
• Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular SurgeryCompletedNCT01662856Phase 3Results posted
• A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's DiseaseCompletedNCT01561053Phase 2/3Results posted
• Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary ImmunodeficiencyCompletedNCT01465958Phase 4Results posted
• A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial OcclusionCompletedNCT01222117Phase 2Results posted
• Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin DeficiencyCompletedNCT01213043Phase 2Results posted
• Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant RecipientsCompletedNCT01131065Phase 3Results posted
• A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke PatientsCompletedNCT01014975Phase 1/2Results posted
• Use of Antithrombin in Cardiac Surgery With Cardiopulmonary BypassCompletedNCT00823082Phase 2Results posted
• Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal FluidCompletedNCT00742417Phase 2Results posted
• Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic PurpuraCompletedNCT00699140Phase 3Results posted
• Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to HemostasisCompletedNCT00684047Phase 2/3Results posted
• Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric SubjectsCompletedNCT00634569Phase 4Results posted
• Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand PatientsTerminatedNCT00555555Phase 4Results posted
• IGIV Study for Chronic ITP Patients Ages 3-70CompletedNCT00511147Phase 3Results posted
• Deposition of Inhaled Prolastin in Cystic Fibrosis PatientsCompletedNCT00486837Phase 2Results posted
• A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary ImmunodeficiencyCompletedNCT00389324Phase 2Results posted
• Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia ACompletedNCT00323856Phase 4Results posted
• Safety, Pharmacokinetics and Efficacy of an ATIII ConcentrateTerminatedNCT00319228Phase 2/3Results posted
• The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) DeficiencyCompletedNCT00301366Phase 3Results posted
• Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient AdultsCompletedNCT00295061Phase 3Results posted
• Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)CompletedNCT00263887Phase 2Results posted
• Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular DegenerationCompletedNCT00220805Phase 2Results posted
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple SclerosisCompletedNCT00220779Phase 2Results posted
• Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00220740Phase 3Results posted
• Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITPCompletedNCT00220727Phase 2Results posted
• Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).CompletedNCT07264517Phase 2
• Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 PneumoniaTerminatedNCT05531149Phase 3
• Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)TerminatedNCT05170269Phase 3
• Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 PatientsTerminatedNCT04883138Phase 1
• FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical ProphylaxisWithdrawnNCT04636268Phase 3
• Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19CompletedNCT04576728Phase 2
• A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)CompletedNCT04547127Phase 2
• Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19CompletedNCT04495101Phase 2
• Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)CompletedNCT04432324Phase 2
• Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyWithdrawnNCT03814798Phase 3
• Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease PatientsCompletedNCT03113812Phase 1
• This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)CompletedNCT02859909Phase 3
• Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand DiseaseWithdrawnNCT02472665Phase 4
• An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)CompletedNCT02139657Phase 1
• Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)CompletedNCT01983241Phase 3
• A Clinical Trial of Zutectra in Patients Who Recently Received a Liver TransplantCompletedNCT01856413Phase 3
• Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With InhibitorsStatus unknownNCT01505946
• Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)CompletedNCT01481493Phase 2
• Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAPCompletedNCT01420744Phase 2

← Grifols overview and focus areas